1. Home
  2. MRKR vs AAME Comparison

MRKR vs AAME Comparison

Compare MRKR & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • AAME
  • Stock Information
  • Founded
  • MRKR N/A
  • AAME 1968
  • Country
  • MRKR United States
  • AAME United States
  • Employees
  • MRKR N/A
  • AAME N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • AAME Life Insurance
  • Sector
  • MRKR Health Care
  • AAME Finance
  • Exchange
  • MRKR Nasdaq
  • AAME Nasdaq
  • Market Cap
  • MRKR 35.8M
  • AAME 34.5M
  • IPO Year
  • MRKR N/A
  • AAME N/A
  • Fundamental
  • Price
  • MRKR $3.10
  • AAME $1.64
  • Analyst Decision
  • MRKR Strong Buy
  • AAME
  • Analyst Count
  • MRKR 1
  • AAME 0
  • Target Price
  • MRKR $19.00
  • AAME N/A
  • AVG Volume (30 Days)
  • MRKR 26.1K
  • AAME 3.3K
  • Earning Date
  • MRKR 11-14-2024
  • AAME 11-12-2024
  • Dividend Yield
  • MRKR N/A
  • AAME 2.44%
  • EPS Growth
  • MRKR N/A
  • AAME N/A
  • EPS
  • MRKR N/A
  • AAME N/A
  • Revenue
  • MRKR $5,395,849.00
  • AAME $185,929,000.00
  • Revenue This Year
  • MRKR $35.94
  • AAME N/A
  • Revenue Next Year
  • MRKR N/A
  • AAME N/A
  • P/E Ratio
  • MRKR N/A
  • AAME N/A
  • Revenue Growth
  • MRKR 79.04
  • AAME 0.35
  • 52 Week Low
  • MRKR $2.44
  • AAME $1.43
  • 52 Week High
  • MRKR $6.16
  • AAME $3.00
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 42.91
  • AAME 48.50
  • Support Level
  • MRKR $2.91
  • AAME $1.53
  • Resistance Level
  • MRKR $3.25
  • AAME $1.76
  • Average True Range (ATR)
  • MRKR 0.38
  • AAME 0.08
  • MACD
  • MRKR -0.11
  • AAME -0.01
  • Stochastic Oscillator
  • MRKR 17.72
  • AAME 39.25

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and innovative peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets. It is also developing peptide-based immunotherapeutic vaccines for the treatment of metastatic solid tumors, as well as PolyStart.

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts. It also provides tailored business automobile insurance coverage, on a multi-year contract basis, to state governments and local municipalities, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance. It earns revenue from the collection of premiums and investment income.

Share on Social Networks: